Invesco Pharmaceuticals ETF
$120.92−2.52 (−2.04%)
- 0.58%
- $548M
- +34.5%
- 0.92%
- 0M sh
- $122.87
- low $92.10high $131.68
The ETF.net PJP Grade
B
Score 63 out of 100
- 4 of 9
Score 63 of 100 falls in the B band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.
Cost
The fund’s net expense ratio, ranked against its category.C41 out of 100Rank 5 of 9Mission
Whether the fund did what it promised, tested against its stated mandate.A78 out of 100Rank 2 of 6Risk
How the fund held up when markets fell: downside volatility, drawdowns and tail loss.A75 out of 100Rank 2 of 9Tradability
How easy the fund is to trade: daily volume, and how far its price strays from net asset value.B65 out of 100Rank 4 of 9Holdings
How concentrated the fund is, and how complete and current its disclosed holdings are.A80 out of 100Rank 2 of 9Durability
Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.B64 out of 100Rank 5 of 9
Our read on PJP
BMost pharma ETFs just weight the biggest drugmakers. PJP instead runs a rules-based screen (price and earnings momentum, quality, management action, value) over US pharma names and rebuilds the roughly 30-stock lineup four times a year.
The fund seeks capital appreciation by investing primarily in pharmaceutical companies selected through the Dynamic Pharmaceutical Intellidex Index.
Why people hold it
- Stock-picking logic in an index wrapper: the Dynamic Pharmaceutical Intellidex ranks US pharma companies on price momentum, earnings momentum, quality, management action and value.invesco.com
- Rebalanced and reconstituted quarterly in February, May, August and November, so the roster refreshes on a set schedule rather than drifting with market cap.invesco.com
- Trading since 2005, one of the longest-running pharma funds on the shelf, and it has held a several-hundred-million-dollar asset base with quarterly distributions.
Worth knowing
- The active-style screen carries an active-style price: 0.57% a year, versus 0.35% for XPH, 0.36% for PPH and 0.37% for IHE.
- Thinly traded next to its peer group, so spreads can widen. Limit orders and avoiding the opening and closing minutes matter more here.
- Concentrated by design: roughly 30 US pharma stocks, non-diversified, with no biotech or device diversification to soften a single drug-pipeline shock.invesco.com
PJP Holdings
- Stocks
- 29
- 50%
- ABBV
Sectors
- Health Care100.0%
Geography
- United States97.11%
- Ireland2.89%
PJP Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
PJP$13,450
Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | PJP |
|---|---|
| Year to date | +19.0% |
| 1 month | −0.3% |
| 3 months | +4.4% |
| 1 year | +34.5% |
| 3 years | +21.2% |
| 5 years | +11.0% |
| 10 years | +8.6% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | PJP |
|---|---|---|
| 2026 YTD | +19.0% | |
| 2025 | +28.0% | |
| 2024 | +9.6% | |
| 2023 | −2.2% | |
| 2022 | −2.2% | |
| 2021 | +14.6% | |
| 2020 | +11.3% |
PJP in the news
PJP Dividends
- 0.92%
- $1.13
- $0.30 per share
- Quarterly
Distribution history
PJP Risk
- 14.4%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 1.07
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −17.5%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.44
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
PJP Cost
0.58%
PJP0.58%
- The middle half of Pharma & Therapeutics funds
- Median 0.58%
4 of the 9 Pharma & Therapeutics funds charge less.
Other funds in Pharma & Therapeutics
- BIHEiShares U.S. Pharmaceuticals ETFExpense ratio 0.37%1 year return +37.5%
- BXPHState Street SPDR S&P Pharmaceuticals ETFExpense ratio 0.35%1 year return +35.9%
- BPBPHPortfolio Building Block World Pharma and Biotech Index ETFExpense ratio 0.13%1 year return —
- BFTXHFirst Trust Nasdaq Pharmaceuticals ETFExpense ratio 0.60%1 year return +43.8%
- COZEMRoundhill Investments - GLP-1 & Weight Loss ETFExpense ratio 0.59%1 year return +3.7%